Background: Hepatocellular carcinoma (HCC) represents the sixth and the fourth most common cancer worldwide and Egypt, respectively. Inflammatory response and nutrition status play a huge role in cancer occurrence. Based on this, many prognostic scores have been evolved such as neutrophil-to-lymphocyte ratio, prognostic nutritional index, and aminotransferase-to-platelet index. HALP and ACLR scores are of those recently developed prognostic score. HALP achieved significant level as a predictor for treatment outcome among HCC patients treated with sorafenib at cut off point of 42.9 with sensitivity of 75.7% and specificity of 86.3%. And, ACLR achieved significant level as a predictor for treatment outcome among HCC patients treated with sorafenib at cut off point of 75.6 with sensitivity of 78.4% and specificity of 82.2%.